Pleurocidin-family cationic antimicrobial peptides are cytolytic for breast carcinoma cells and prevent growth of tumor xenografts

Breast Cancer Research

Volumn 13, Issue 5, 2011, Pages

  Hilchie, Ashley L ^a   Doucette, Carolyn D ^a   Pinto, Devanand M ^a,b   Patrzykat, Aleksander ^b   Douglas, Susan ^a,b   Hoskin, David W ^a  

^a DALHOUSIE UNIVERSITY   (Canada)

^b NATIONAL RESEARCH COUNCIL CANADA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; LACTATE DEHYDROGENASE; PHOSPHATASE; POLYPEPTIDE ANTIBIOTIC AGENT; REACTIVE OXYGEN METABOLITE; ANTIMICROBIAL CATIONIC PEPTIDE; ANTINEOPLASTIC AGENT; CISPLATIN; FISH PROTEIN; PLEUROCIDIN;

ANIMAL CELL; ARTICLE; BREAST CARCINOMA; CARCINOMA CELL; CELL VIABILITY; CONTROLLED STUDY; FEMALE; FIBROBLAST; FLOW CYTOMETRY; HEMOLYSIS; HUMAN; HUMAN CELL; MITOCHONDRIAL MEMBRANE; MOUSE; NONHUMAN; SCANNING ELECTRON MICROSCOPY; TUMOR XENOGRAFT; AMINO ACID SEQUENCE; ANIMAL; BREAST TUMOR; CARCINOMA; CELL CULTURE; CELL MEMBRANE; CYTOLOGY; DOSE RESPONSE; DRUG EFFECT; DRUG RESISTANCE; DRUG SCREENING; METABOLISM; MOLECULAR GENETICS; MOUSE MUTANT; PATHOLOGY; UMBILICAL VEIN; VASCULAR ENDOTHELIUM;

AMINO ACID SEQUENCE; ANIMALS; ANTIMICROBIAL CATIONIC PEPTIDES; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CARCINOMA; CELL MEMBRANE; CELLS, CULTURED; CISPLATIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; ENDOTHELIUM, VASCULAR; FEMALE; FIBROBLASTS; FISH PROTEINS; HUMANS; MICE; MICE, SCID; MITOCHONDRIAL MEMBRANES; MOLECULAR SEQUENCE DATA; REACTIVE OXYGEN SPECIES; UMBILICAL VEINS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 80054828685     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr3043     Document Type: Article

References (38)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009, 59:225-249. 10.3322/caac.20006, 19474385.
2. Maughan KL, Lutterbie MA, Ham PS. Treatment of breast cancer. Am Fam Physician 2010, 81:1339-1346.
3. Donnelly JG. Pharmacogenetics in cancer chemotherapy: balancing toxicity and response. Ther Drug Monit 2004, 26:231-235. 10.1097/00007691-200404000-00026, 15228171.
4. Naumov GN, Townson JL, MacDonald IC, Wilson SM, Bramwell VH, Groom AC, Chambers AF. Ineffectiveness of doxorubicin treatment on solitary dormant mammary carcinoma cells or late-developing metastases. Breast Cancer Res Treat 2003, 82:199-206. 10.1023/B:BREA.0000004377.12288.3c, 14703067.
5. Katragadda S, Budda B, Anand BS, Mitra AK. Role of efflux pumps and metabolising enzymes in drug delivery. Expert Opin Drug Deliv 2005, 2:683-705. 10.1517/17425247.2.4.683, 16296794.
6. Smith LL, Brown K, Carthew P, Lim CK, Martin EA, Styles J, White IN. Chemoprevention of breast cancer by tamoxifen: risks and opportunities. Crit Rev Toxicol 2000, 30:571-594. 10.1080/10408440008951120, 11055836.
7. Dean-Colomb W, Esteva FJ. Her2-positive breast cancer: herceptin and beyond. Eur J Cancer 2008, 44:2806-2812. 10.1016/j.ejca.2008.09.013, 19022660.
8. Nahta R, Yu D, Hung MC, Hortobagyi GN, Esteva FJ. Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer. Nat Clin Pract Oncol 2006, 3:269-280. 10.1038/ncponc0509, 16683005.
9. Hoskin DW, Ramamoorthy A. Studies on anticancer activities of antimicrobial peptides. Biochim Biophys Acta 2008, 1778:357-375. 10.1016/j.bbamem.2007.11.008, 2238813, 18078805.
10. Hancock RE. Peptide antibiotics. Lancet 1997, 349:418-422. 10.1016/S0140-6736(97)80051-7, 9033483.
11. Koo CY, Sen YP, Bay BH, Yip GW. Targeting heparan sulfate proteoglycans in breast cancer treatment. Recent Pat Anticancer Drug Discov 2008, 3:151-158. 10.2174/157489208786242278, 18991783.
12. Papo N, Shahar M, Eisenbach L, Shai Y. A novel lytic peptide composed of DL-amino acids selectively kills cancer cells in culture and in mice. J Biol Chem 2003, 278:21018-21023. 10.1074/jbc.M211204200, 12646578.
13. Mader JS, Salsman J, Conrad DM, Hoskin DW. Bovine lactoferricin selectively induces apoptosis in human leukemia and carcinoma cell lines. Mol Cancer Ther 2005, 4:612-624.
14. Kim S, Kim SS, Bang YJ, Kim SJ, Lee BJ. In vitro activities of native and designed peptide antibiotics against drug sensitive and resistant tumor cell lines. Peptides 2003, 24:945-953. 10.1016/S0196-9781(03)00194-3, 14499271.
15. Hansel W, Enright F, Leuschner C. Destruction of breast cancers and their metastases by lytic peptide conjugates in vitro and in vivo. Mol Cell Endocrinol 2007, 260-262:183-189.
16. Leuschner C, Enright FM, Gawronska B, Hansel W. Membrane disrupting lytic peptide conjugates destroy hormone dependent and independent breast cancer cells in vitro and in vivo. Breast Cancer Res Treat 2003, 78:17-27. 10.1023/A:1022169525521, 12611453.
17. Chen Y, Xu X, Hong S, Chen J, Liu N, Underhill CB, Creswell K, Zhang L. RGD-Tachyplesin inhibits tumor growth. Cancer Res 2001, 61:2434-2438.
18. Mader JS, Hoskin DW. Cationic antimicrobial peptides as novel cytotoxic agents for cancer treatment. Expert Opin Investig Drugs 2006, 15:933-946. 10.1517/13543784.15.8.933, 16859395.
19. Berge G, Eliassen LT, Camilio KA, Bartnes K, Sveinbjornsson B, Rekdal O. Therapeutic vaccination against a murine lymphoma by intratumoral injection of a cationic anticancer peptide. Cancer Immunol Immunother 2010, 59:1285-1294. 10.1007/s00262-010-0857-6, 20422410.
20. Hui L, Leung K, Chen HM. The combined effects of antibacterial peptide cecropin A and anti-cancer agents on leukemia cells. Anticancer Res 2002, 22:2811-2816.
21. Johnstone SA, Gelmon K, Mayer LD, Hancock RE, Bally MB. In vitro characterization of the anticancer activity of membrane-active cationic peptides, I: Peptide-mediated cytotoxicity and peptide-enhanced cytotoxic activity of doxorubicin against wild-type and p-glycoprotein over-expressing tumor cell lines. Anticancer Drug Des 2000, 15:151-160.
22. Patrzykat A, Gallant JW, Seo JK, Pytyck J, Douglas SE. Novel antimicrobial peptides derived from flatfish genes. Antimicrob Agents Chemother 2003, 47:2464-2470. 10.1128/AAC.47.8.2464-2470.2003, 166104, 12878506.
23. Tosteson MT, Holmes SJ, Razin M, Tosteson DC. Melittin lysis of red cells. J Membr Biol 1985, 87:35-44. 10.1007/BF01870697, 4057243.
24. Banfield BW, Leduc Y, Esford L, Schubert K, Tufaro F. Sequential isolation of proteoglycan synthesis mutants by using herpes simplex virus as a selective agent: evidence for a proteoglycan-independent virus entry pathway. J Virol 1995, 69:3290-3298. 189040, 7745676.
25. McCormick C, Leduc Y, Martindale D, Mattison K, Esford LE, Dyer AP, Tufaro F. The putative tumor suppressor EXT1 alters the expression of cell-surface heparan sulfate. Nat Genet 1998, 19:158-161. 10.1038/514, 9620772.
26. Kuma A, Hatano M, Matsui M, Yamamoto A, Nakaya H, Yoshimori T, Ohsumi Y, Tokuhisa T, Mizushima N. The role of autophagy during the early neonatal starvation period. Nature 2004, 432:1032-1036. 10.1038/nature03029, 15525940.
27. Vellonen KS, Honkakoski P, Urtti A. Substrates and inhibitors of efflux proteins interfere with the MTT assay in cells and may lead to underestimation of drug toxicity. Eur J Pharm Sci 2004, 23:181-188. 10.1016/j.ejps.2004.07.006, 15451006.
28. Silvestri ME, Sundqvist VA. An investigation into the heparin-binding properties of a synthetic peptide deduced from the antigenic domain 2 of human cytomegalovirus glycoprotein B. Scand J Immunol 2001, 53:282-289. 10.1046/j.1365-3083.2001.00878.x, 11251886.
29. Mader JS, Richardson A, Salsman J, Top D, de Antueno R, Duncan R, Hoskin DW. Bovine lactoferricin causes apoptosis in Jurkat T-leukemia cells by sequential permeabilization of the cell membrane and targeting of mitochondria. Exp Cell Res 2007, 313:2634-2650. 10.1016/j.yexcr.2007.05.015, 17570361.
30. Iida J, Meijne AM, Knutson JR, Furcht LT, McCarthy JB. Cell surface chondroitin sulfate proteoglycans in tumor cell adhesion, motility and invasion. Semin Cancer Biol 1996, 7:155-162. 10.1006/scbi.1996.0021, 8773301.
31. de Kroon AI, Dolis D, Mayer A, Lill R, de Kruijff B. Phospholipid composition of highly purified mitochondrial outer membranes of rat liver and Neurospora crassa: is cardiolipin present in the mitochondrial outer membrane?. Biochim Biophys Acta 1997, 1325:108-116. 10.1016/S0005-2736(96)00240-4, 9106488.
32. Indran IR, Tufo G, Pervaiz S, Brenner C. Recent advances in apoptosis, mitochondria and drug resistance in cancer cells. Biochim Biophys Acta 2011, 1807:735-745. 10.1016/j.bbabio.2011.03.010, 21453675.
33. Sy LK, Yan SC, Lok CN, Man RY, Che CM. Timosaponin A-III induces autophagy preceding mitochondria-mediated apoptosis in HeLa cancer cells. Cancer Res 2008, 68:10229-10237. 10.1158/0008-5472.CAN-08-1983, 19074891.
34. Charafe-Jauffret E, Ginestier C, Iovino F, Wicinski J, Cervera N, Finetti P, Hur MH, Diebel ME, Monville F, Dutcher J, Brown M, Viens P, Xerri L, Bertucci F, Stassi G, Dontu G, Bimbaum D, Wicha MS. Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature. Cancer Res 2009, 69:1302-1313. 10.1158/0008-5472.CAN-08-2741, 2819227, 19190339.
35. Jia L, Noker PE, Piazza GA, Leuschner C, Hansel W, Gorman GS, Coward LU, Tomaszewski J. Pharmacokinetics and pharmacodynamics of Phor21-βCG(ala), a lytic peptide conjugate. J Pharm Pharmacol 2008, 60:1441-1448. 2825277, 18957164.
36. Makovitzki A, Fink A, Shai Y. Suppression of human solid tumor growth in mice by intratumor and systemic inoculation of histidine-rich and pH-dependent host defense-like lytic peptides. Cancer Res 2009, 69:3458-3463. 10.1158/0008-5472.CAN-08-3021, 19351852.
37. Riedl S, Rinner B, Asslaber M, Schaider H, Walzer S, Novak A, Lohner K, Zweytick D. In search of a novel target: phosphatidylserine exposed by non-apoptotic tumor cells and metastases of malignancies with poor treatment efficacy. Biochim Biophys Acta 2011, 1808:2638-2645. 10.1016/j.bbamem.2011.07.026, 3175029, 21810406.
38. Patrzykat A, Friedrich CL, Zhang L, Mendoza V, Hancock RE. Sublethal concentrations of pleurocidin-derived antimicrobial peptides inhibit macromolecular synthesis in Escherichia coli. Antimicrob Agents Chemother 2002, 46:605-614. 10.1128/AAC.46.3.605-614.2002, 127508, 11850238.